Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)

Go back to Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)

Eiger BioPharmaceuticals (EIGR) to Resume Trading at 4:35 pm ET

October 16, 2018 4:28 PM EDT

Eiger BioPharmaceuticals (NASDAQ: EIGR) to Resume Trading at 4:35 pm ET

... More